BRIEF-Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 Million

Reuters12-23

Dec 23 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O:

REVIVA PHARMACEUTICALS: RECOVER-2 TRIAL PROJECTED TO COST ABOUT $60 MILLION
REVIVA PHARMACEUTICALS: MAY INITIATE PHASE 3 TRIAL OF BRILAROXAZINE FOR NEGATIVE SYMPTOMS OR BIPOLAR DISORDER IN Q2 2026
REVIVA PHARMACEUTICALS: NEGATIVE SYMPTOMS/BIPOLAR TRIAL IS PROJECTED TO COST ABOUT $30 MILLION

Source text: [ID:n0001437749-25-038602]

Further company coverage: RVPH.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593046490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593046490","market":"us","top_or_hot":-1,"title":"BRIEF-Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 Million</title></head><body><p><span>Dec 23 (Reuters)</span><span> - </span>Reviva Pharmaceuticals Holdings Inc <span>RVPH.O</span>:</p><ul><li><p>REVIVA PHARMACEUTICALS: RECOVER-2 TRIAL PROJECTED TO COST ABOUT $60 MILLION</p></li><li><p>REVIVA PHARMACEUTICALS: MAY INITIATE PHASE 3 TRIAL OF BRILAROXAZINE FOR NEGATIVE SYMPTOMS OR BIPOLAR DISORDER IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>REVIVA PHARMACEUTICALS: NEGATIVE SYMPTOMS/BIPOLAR TRIAL IS PROJECTED TO COST ABOUT $30 MILLION</p></li></ul><p>Source text: [ID:n0001437749-25-038602]</p><p>Further company coverage: <span>RVPH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-23 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 Million</title></head><body><p><span>Dec 23 (Reuters)</span><span> - </span>Reviva Pharmaceuticals Holdings Inc <span>RVPH.O</span>:</p><ul><li><p>REVIVA PHARMACEUTICALS: RECOVER-2 TRIAL PROJECTED TO COST ABOUT $60 MILLION</p></li><li><p>REVIVA PHARMACEUTICALS: MAY INITIATE PHASE 3 TRIAL OF BRILAROXAZINE FOR NEGATIVE SYMPTOMS OR BIPOLAR DISORDER IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>REVIVA PHARMACEUTICALS: NEGATIVE SYMPTOMS/BIPOLAR TRIAL IS PROJECTED TO COST ABOUT $30 MILLION</p></li></ul><p>Source text: [ID:n0001437749-25-038602]</p><p>Further company coverage: <span>RVPH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0M9:1","article_id":"2593046490","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593046490","pubTimestamp":1766495431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 MillionDec 23  - Reviva Pharmaceuticals Holdings Inc RVPH.O:REVIVA PHARMACEUTICALS: RECOVER-2 TRIAL PROJECTED TO COST ABOUT $60 MILLIONREVIVA PHARMACEUTICALS: MAY INITIATE PHASE 3 TRIAL OF BRILAROXAZINE FOR NEGATIVE SYMPTOMS OR BIPOLAR DISORDER IN Q2 2026REVIVA PHARMACEUTICALS: NEGATIVE SYMPTOMS/BIPOLAR TRIAL IS PROJECTED TO COST ABOUT $30 MILLIONSource text: [ID:n0001437749-25-038602]Further company coverage: RVPH.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RVPH":"Reviva Pharmaceuticals Holdings, Inc."},"translate_title":"简介-Reviva Pharmaceuticals Recover-2试验预计耗资约6000万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVPH":0.9},"content_text":"BRIEF-Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 MillionDec 23 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O:REVIVA PHARMACEUTICALS: RECOVER-2 TRIAL PROJECTED TO COST ABOUT $60 MILLIONREVIVA PHARMACEUTICALS: MAY INITIATE PHASE 3 TRIAL OF BRILAROXAZINE FOR NEGATIVE SYMPTOMS OR BIPOLAR DISORDER IN Q2 2026REVIVA PHARMACEUTICALS: NEGATIVE SYMPTOMS/BIPOLAR TRIAL IS PROJECTED TO COST ABOUT $30 MILLIONSource text: [ID:n0001437749-25-038602]Further company coverage: RVPH.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593046490","isCrawlerRequest":true}